Idarubicine Accord

Idarubicin Hydrochloride, the active ingredient in Idarubicine Accord, is an anthracycline antibiotic presented as an injection solution for intravenous use. It is employed in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia in adult and pediatric patients. The drug is formulated for sterile infusion and is indicated for patients with newly diagnosed or relapsed disease.

GNH USA supplies Idarubicine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality and regulatory compliance across EU and global markets.

Idarubicine Accord, an anthracycline chemotherapy, is used in the treatment of acute leukemias. - Acute Myeloid Leukemia (AML): induces remission and reduces leukemic burden in newly diagnosed or relapsed AML patients. - Acute Lymphoblastic Leukemia (ALL): contributes to disease control and improves survival outcomes in ALL patients.

Idarubicine Accord may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting - Alopecia (hair loss) - Fatigue - Myelosuppression (neutropenia, anemia, thrombocytopenia) - Mucositis - Diarrhea

Serious or Rare Side Effects: - Cardiotoxicity leading to heart failure - Severe infections secondary to neutropenia - Hemorrhage due to thrombocytopenia - Secondary malignancies - Severe infusion‑related reactions - Hepatic toxicity

When using Idarubicine Accord, careful monitoring and risk mitigation are essential. - Cardiac monitoring: baseline and periodic assessment of left ventricular function is recommended. - Hematologic monitoring: regular complete blood counts to detect neutropenia, anemia, and thrombocytopenia. - Liver function monitoring: evaluate transaminases and bilirubin before and during therapy. - Renal function monitoring: assess creatinine clearance as dosage may require adjustment. - Pregnancy and breastfeeding: use only if the potential benefit justifies the potential risk; safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicine Accord can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use with other anthracyclines (e.g., daunorubicin) may increase cardiotoxic risk. - Combination with known cardiotoxic agents such as trastuzumab should be avoided.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may raise idarubicin exposure. - Anticoagulants (e.g., warfarin) can heighten bleeding risk. - Other myelosuppressive chemotherapy agents may exacerbate bone‑marrow suppression.